• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Balkan journal of medical genetics: BJMG >DIFFERENTIAL EXPRESSION OF FGFRs SIGNALING PATHWAY COMPONENTS IN BLADDER CANCER: A STEP TOWARD PERSONALIZED MEDICINE
【24h】

DIFFERENTIAL EXPRESSION OF FGFRs SIGNALING PATHWAY COMPONENTS IN BLADDER CANCER: A STEP TOWARD PERSONALIZED MEDICINE

机译：FGFRS信号通路组分在膀胱癌中的差异表达：迈向个性化医学的一步

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Variations Improper activation and inappropriate expression of fibroblast growth factor receptors (FGFRs) in cancer suggests that they can act as therapeutic targets. Fibroblast growth factor receptor inhibitors are currently employed in clinical trials of different cancers. Regarding the essence and the importance of the personalized medicine, mainly mirrored by remarkable inter-individual variations in different populations, we aimed to perform a pilot study to address FGFR1 and FGFR3 expression levels and their correlation with the clinicopathological features in Iranian patients with bladder cancer (BC). Paired tumor and adjacent non tumor tissue samples along with their clinico-pathological parameters were obtained from 50 cases diagnosed with BC in different stages and grades. The mRNA expressions of FGFR1 and FGFR3 in tissue samples were determined by real-time polymerase chain reaction (real-time PCR). The expression levels of FGFR3 were significantly higher in tumor tissues when compared to adjacent normal tissues (p = 0.007), regardless of the stages and grades of the tumor. Over expression was associated with cigarette smoking (p = 0.037) and family history for cancer (p = 0.004). Decreased expression of FGFR1 was observed, remarkably evident in high-grade tumors (p = 0.047), while over expression was detected in low-grade samples. This pilot study clearly suggests that in Iranian BC patients FGFR1 and FGFR3 expression patterns are different, and also highly distinctive with regard to the tumor's stage and grade. Such particular expression patterns may indicate their special values to be employed for interventional studies aiming targeted therapy. Further studies with a larger sample size are needed to validate our results.
机译：癌症中的含有不当的激活和不当表达不当癌症的增生因子受体（FGFRs）表明它们可以作为治疗靶标。成纤维细胞生长因子受体抑制剂目前用于不同癌症的临床试验。关于个性化医学的本质和重要性，主要是由于不同群体的卓越间变异，我们旨在进行试点研究，以解决FGFR1和FGFR3表达水平及其与膀胱癌患者临床病理特征的相关性（公元前）。配对肿瘤和相邻的非肿瘤组织样品以及其临床病理参数的50例患者在不同阶段和等级中诊断为50例。通过实时聚合酶链反应（实时PCR）测定组织样品中FGFR1和FGFR3的mRNA表达。与相邻的正常组织相比（p = 0.007）相比，肿瘤组织的FGFR3的表达水平显着较高（P = 0.007），无论肿瘤的阶段和等级如何。过度表达与香烟吸烟有关（P = 0.037）和癌症的家族史（P = 0.004）。观察到FGFR1的表达减少，在高等肿瘤中显着明显（p = 0.047），而在低级样品中检测到过度表达。该试点研究明确表明，在伊朗BC患者中，FGFR1和FGFR3表达模式不同，并且对于肿瘤的阶段和等级也具有高度独特的。这种特殊表达模式可以指示其特殊值用于用于旨在靶向治疗的介入研究。需要更大的样本量的进一步研究来验证我们的结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号